Madrigal Pharmaceuticals
MDGL
55 hedge funds and large institutions have $9.44M invested in Madrigal Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 22 reducing their positions, and 23 closing their positions.
1,800% more call options, than puts
Call options by funds: $19K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $10.1M → $9.44M (-$611K)
19% less funds holding
Funds holding: 68 → 55 (-13)
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
55% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$693K |
| 2 |
AC
Armistice Capital
New York
|
+$206K |
| 3 |
Millennium Management
New York
|
+$168K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$84.1K |
| 5 |
AGM
Alpine Global Management
New York
|
+$66.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$804K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$367K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$295K |
| 4 |
State Street
Boston,
Massachusetts
|
-$293K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$282K |
MDGL Hedge Fund Activity: Q2 2016 in Review
55 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2016, worth a combined $9.44M — down 6.1% from $10.1M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of MDGL and 11 opened new positions — a net loss of 12 holders — while 22 trimmed existing stakes and 10 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $693K. The largest seller was BlackRock Fund Advisors, cutting an estimated $804K.
- 55 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2016, down from 68 in Q1 2016.
- Funds reported $9.44M of Madrigal Pharmaceuticals stock for Q2 2016, down 6.1% quarter-over-quarter.
- 11 funds opened new Madrigal Pharmaceuticals positions in Q2 2016 and 23 closed out, a net change of -12 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2016 was Baker Bros. Advisors, an estimated $693K added.
- The largest Madrigal Pharmaceuticals seller in Q2 2016 was BlackRock Fund Advisors, an estimated $804K sold.
Based on aggregated 13F filings for Q2 2016.